1. Home
  2. > Healthcare
  3. > Health Services Market Trends
Idiopathic Pulmonary Fibrosis - Epidemiology Forecast - 2032

Idiopathic Pulmonary Fibrosis - Epidemiology Forecast - 2032

  • August 2022
  • 109 pages
  • ID: 6316454
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Idiopathic Pulmonary Fibrosis - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Idiopathic Pulmonary Fibrosis Understanding

Idiopathic Pulmonary Fibrosis Overview
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. The disease usually affects people in later stage of their life. Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung.
The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough
Idiopathic Pulmonary Fibrosis Diagnosis
Careful evaluation of clinical, laboratory, x-ray data and high resolution computed tomography (HRCT), and at times lung biopsy material to make a confident diagnosis. This is usually done by a respiratory specialist in union with other specialists with interest in IPF. The diagnosis of IPF relies on the clinician to assimilate and correlate the clinical, laboratory, radiologic, and/or pathologic data.
There are several diagnostic tools available and the consensus guidelines have been well defined to identify IPF. Pulmonary function tests are performed to assess for restrictive lung disease which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity. When IPF is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging is like x-rays is done but when they are not detailed enough to confirm IPF. High-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.
Idiopathic Pulmonary Fibrosis Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), age-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis, and severity-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis scenario of Idiopathic Pulmonary Fibrosis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Idiopathic Pulmonary Fibrosis Detailed Epidemiology Segmentation
• The total diagnosed prevalent cases of IPF in the 7MM was 194,878 cases in 2021 which is expected to rise, at a CAGR of 1.1% during the study period (2019–2032).
• The highest diagnosed prevalent cases of IPF was accounted by the US in 2021, with 94,736 cases in the 7MM, which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population.
• Among the European countries, Germany had the highest diagnosed prevalent population of IPF with 20,774 cases, followed by the UK with 15,760 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
• In the epidemiology model, we have considered four age groups for the categorization of IPF i.e. 18–39 years, 40–59 years, 60–79 years, and >80 years. As per our analysis, a highest percentage of diagnosed prevalent cases was observed in age group 60–79, in all the 7MM countries.
• As per the analysis the males are predominantly affected highly with IPF than females. In 2021, there were 121,389 males and 73,488 females affected by IPF in the 7MM.
• Japan accounted for 21,246 cases of total diagnosed prevalent cases of IPF in 2021 which are anticipated to rise by the end of 2032.

Scope of the Report
• The report covers the descriptive overview of Idiopathic Pulmonary Fibrosis, explaining its causes, signs, and symptoms, and pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden.
• The report provides the segmentation of the disease epidemiology for 7MM by segmented by diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), age-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis, and severity-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.

Report Highlights
• 11-Year Forecast of Idiopathic Pulmonary Fibrosis.
• The 7MM Coverage.
• Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.
• Gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.
• Age-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.
• Severity-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.

Key Questions Answered
• What are the disease risk, burdens, and unmet needs of Idiopathic Pulmonary Fibrosis?
• What is the historical Idiopathic Pulmonary Fibrosis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Idiopathic Pulmonary Fibrosis at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Idiopathic Pulmonary Fibrosis?
• Out of the countries mentioned above, which country would have the highest patient population of Idiopathic Pulmonary Fibrosis during the forecast period (2022–2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Reasons to buy
The Idiopathic Pulmonary Fibrosis report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MMIdiopathic Pulmonary Fibrosis epidemiology.
• The Idiopathic Pulmonary Fibrosis epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Idiopathic Pulmonary Fibrosis epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019–2032

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Myelofibrosis - Epidemiology Forecast - 2032

  • $ 3950
  • September 2022
  • 110 pages

‘Myelofibrosis - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, the EU-5 (Germany, Spain, Italy, ...

  • United States
  • Spain
  • Epidemiology
  • Industry analysis

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on